RHYTHM PHARMACEUTICALS, INC. Logo

RHYTHM PHARMACEUTICALS, INC.

Develops precision medicines for rare genetic diseases causing severe obesity and hyperphagia.

RYTM | US

Overview

Corporate Details

ISIN(s):
US76243J1051
LEI:
Country:
United States of America
Address:
222 BERKELEY STREET, 2116 BOSTON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Rhythm Pharmaceuticals, Inc. is a global, commercial-stage biopharmaceutical company dedicated to developing and commercializing precision medicines for rare neuroendocrine diseases. The company focuses on treating conditions characterized by hyperphagia (insatiable hunger) and severe obesity that stem from rare genetic deficiencies. Its lead therapeutic, setmelanotide (marketed as IMCIVREE), is a precision medicine designed to address the root cause of these disorders by targeting the melanocortin-4 receptor (MC4R) pathway. Rhythm is advancing a portfolio of treatment options to transform the lives of patients and families affected by these debilitating conditions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-04 13:05
Regulatory News Service
8-K - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)
English 126.1 KB

Automate Your Workflow. Get a real-time feed of all RHYTHM PHARMACEUTICALS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for RHYTHM PHARMACEUTICALS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for RHYTHM PHARMACEUTICALS, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
ANTEROGEN CO., LTD. Logo
Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.
South Korea 065660
Antibiotice S.A. Logo
Develops and manufactures generic medicines and APIs, specializing in anti-infectives.
Romania ATB
Apellis Pharmaceuticals, Inc. Logo
Developing novel C3 therapies for diseases in ophthalmology, nephrology, and hematology.
United States of America APLS
Apimeds Pharmaceuticals US, Inc. Logo
Biopharma developing non-narcotic bee venom therapies for osteoarthritis pain and inflammation.
United States of America APUS
Apogee Therapeutics, Inc. Logo
Developing novel antibody biologics for immunological and inflammatory (I&I) diseases.
United States of America APGE
Apollomics Inc. Logo
A clinical-stage biopharma developing targeted oncology therapies for hard-to-treat cancers.
United States of America APLM
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany APPH
Develops DNA tech for genetic medicine, molecular diagnostics, and supply chain security.
United States of America APDN
Applied Therapeutics, Inc. Logo
Develops treatments for rare metabolic and central nervous system (CNS) disorders.
United States of America APLT
Aprea Therapeutics, Inc. Logo
Developing precision cancer therapies targeting DNA Damage Response for solid tumors.
United States of America APRE

Talk to a Data Expert

Have a question? We'll get back to you promptly.